文献速递治疗药物监测与药物基因组学特殊人群用药

儿童肿瘤队列中实施先发性药物基因组筛查的影响

Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
PubMed 文献 · Clin Pharmacol Ther · 2025-05-07

结果显示16%的个体可能从调整剂量或治疗中获益,涉及别嘌醇、非甾体抗炎药、苯妥英等多种药物。作者建议将药物基因组筛查纳入临床工作流程。

要点

  • 16%的儿童肿瘤患者可能因药物基因组筛查而调整剂量或治疗。
  • 建议将药物基因组筛查整合到临床工作流程中以优化用药。

核心结论

  • 在1,151例儿童肿瘤患者中,16%的个体可能从基于药物基因组筛查的剂量或治疗调整中获益。

主要发现

  • 16%的个体可能受益于 altered drug dosing or treatment。
  • 涉及药物包括别嘌醇、非甾体抗炎药、苯妥英、阿米替林、质子泵抑制剂、伏立康唑、曲马多、可待因、帕罗西汀、他克莫司、拉布立酶和6-巯基嘌呤。

临床怎么用

  • 利用分子诊断获得的遗传数据开展先发性药物基因组筛查,指导药物选择和剂量优化。
  • 将药物基因组筛查纳入临床工作流程以推进儿童肿瘤个体化医疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre-emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence-based recommendations exist for a subset of supportive care drugs and anticancer drugs, including thiopurines, irinotecan, capecitabine, and 5-fluorouracil. In this study, we evaluate the potential impact of pre-emptive pharmacogenetic screening by retrospectively identifying opportunities for dose or treatment adjustments within a national pediatric oncology cohort. Our analysis focused on ten genes and 28 drugs relevant to pediatric oncology, which are included in the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group guidelines. In a cohort of 1,151 pediatric oncology subjects, we identified that 16% of individuals could have benefited from altered drug dosing or treatment. These include dose and treatment recommendations for allopurinol, nonsteroidal anti-inflammatory drugs, phenytoin, amitriptyline, proton pump inhibitors, voriconazole, tramadol, codeine, paroxetine, tacrolimus, rasburicase, and 6-mercaptopurine. As genetic data increasingly becomes available through molecular diagnostics in pediatric oncology, there is a unique opportunity to re-utilize this data for pre-emptive pharmacogenetic screening. Leveraging genetic profiles to guide clinicians in drug selection and dose optimization can improve patient outcomes by enhancing the safety and efficacy of treatments. We therefore recommend incorporating pharmacogenetic screening into clinical workflows to advance personalized medicine in pediatric oncology.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bernsen EC, Verwiel ETP, van der Lee M, et al. Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects. Clin Pharmacol Ther. 2025. PMID: 40331624. doi:10.1002/cpt.3685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。